FPR2 Antibody

What is FPR2 and why is it a significant research target?

FPR2 (formerly known as FPRL1) belongs to the N-formyl peptide receptor family, which includes three members: FPR, FPR-like 1 (FPRL1), and FPR-like 2 (FPRL2). These receptors function as chemotactic G protein-coupled receptors with seven transmembrane domains, predominantly expressed on the surface of phagocytic leukocytes such as neutrophils and monocytes. FPR2 has gained significant research attention due to its crucial role in mediating inflammatory responses and host defense mechanisms by binding to various ligands, including lipoxin A4 and N-formyl-methionyl-leucyl-phenylalanine (fMLP) . Upon activation, FPR2 triggers cellular migration and calcium mobilization, which are vital for effective immune responses. The receptor's ability to modulate immune cell activity makes it a significant target for therapeutic interventions aimed at controlling inflammation and enhancing host defense, with particular relevance to diseases such as Alzheimer's, cancer, and inflammatory conditions .

What detection methods are available when working with FPR2 antibodies?

FPR2 antibodies, such as the mouse monoclonal GM1D6, can be employed in multiple detection methods depending on experimental requirements. Western blotting (WB) represents the most common application, allowing for protein quantification and size determination. For this application, researchers should optimize protein extraction from target tissues, particularly leukocytes, using buffers containing protease inhibitors to prevent degradation. Immunoprecipitation (IP) provides another valuable approach for isolating FPR2 and its binding partners, requiring careful optimization of antibody concentration and incubation conditions . Flow cytometry (FCM) offers a powerful method for quantifying FPR2 expression on specific cell populations, enabling multiparametric analysis when combined with other cellular markers. For optimal results in flow cytometry applications, researchers should consider using conjugated FPR2 antibodies, available with various fluorophores including phycoerythrin (PE), fluorescein isothiocyanate (FITC), and Alexa Fluor conjugates . In all applications, proper controls including isotype controls are essential to distinguish specific from non-specific binding.

How should researchers account for sex-based differences in FPR2 expression and function?

Recent research has revealed significant sex-based differences in FPR2 expression and function that require careful consideration in experimental design. Flow cytometry analysis of peripheral blood mononuclear cells (PBMCs) has demonstrated that FPR2 expression is significantly higher in CD11b+CD14+ classical monocytes from female donors compared to male donors . This sexual dimorphism extends to functional differences, where FPR2-expressing macrophages from female donors exhibit stronger immunosuppressive properties than their male counterparts . When designing experiments involving FPR2, researchers should consider sex as a biological variable, segregating samples by donor sex during analysis. This approach is particularly critical in cancer research, where FPR2 has been identified as a sex-dependent mediator of macrophage function in pancreatic cancer . Experimental protocols should include sex-matched controls, and researchers should avoid pooling samples from different sexes. Additionally, when reporting results, data should be presented with clear delineation of sex differences to enhance reproducibility and clinical relevance.

How can FPR2 antibodies be utilized in cancer immunology research?

FPR2 antibodies provide powerful tools for investigating the role of FPR2 in cancer immunology, particularly in understanding tumor microenvironment (TME) dynamics. When designing experiments to study FPR2 in cancer, researchers should implement multi-parameter flow cytometry panels that combine FPR2 antibodies with markers for different immune cell populations (CD11b, CD14, CD16) and activation states. This approach enables characterization of FPR2 expression patterns across diverse myeloid cell populations within the TME . Importantly, recent research has identified FPR2 as a sex-dependent mediator of macrophage function in pancreatic cancer, highlighting the need for sex-stratified analysis in FPR2 cancer studies . Immunohistochemistry using FPR2 antibodies on tumor sections can reveal spatial distribution of FPR2-expressing cells relative to tumor regions, providing insights into immune exclusion mechanisms. For functional studies, co-culture systems combining FPR2-expressing macrophages with T cells or NK cells can illuminate how FPR2 signaling affects anti-tumor immunity. Researchers should include conditions with FPR2 agonists (like ACT) and antagonists (like WRW4) to manipulate receptor activity and observe downstream effects on immune cell function .

What methodological considerations are important when studying FPR2's role in inflammation resolution?

When investigating FPR2's role in inflammation resolution, researchers must carefully consider both technical and biological variables that may influence experimental outcomes. For in vitro studies, primary human monocytes/macrophages should be isolated with methods that preserve receptor functionality, as excessive manipulation can alter FPR2 expression and responsiveness. When polarizing macrophages to study FPR2 in M1 versus M2 phenotypes, standardized cytokine cocktails should be used, and the polarization state should be verified using established markers beyond FPR2 itself . For functional studies of inflammation resolution, calcium mobilization assays represent a primary readout for FPR2 activation, requiring optimization of loading conditions and signal normalization . When testing FPR2 agonists in resolution models, dose-response curves should span at least five concentrations to accurately determine EC50 values, and time-course experiments should capture both immediate responses and delayed resolution phases . Researchers must be cautious about potential dual activity on FPR1, as many compounds show cross-reactivity between these related receptors. Selective FPR2 agonists with >10,000-fold selectivity over FPR1 are available and should be utilized when studying FPR2-specific effects . Additionally, experiments should include both sexes and report sex-specific outcomes given the documented sexual dimorphism in FPR2 signaling.

How can researchers address specificity concerns when working with FPR2 antibodies?

Ensuring antibody specificity represents a critical challenge in FPR2 research due to the high sequence homology between FPR family members. FPR1 and FPR2 share significant sequence similarity, making cross-reactivity a common concern in antibody-based detection methods . To address this challenge, researchers should implement a multi-faceted validation approach. First, whenever possible, use knockout/knockdown controls to confirm antibody specificity. FPR2-/- cells or tissues provide the gold standard for validating antibody specificity . Additionally, researchers should perform comparative analysis with multiple FPR2 antibodies targeting different epitopes to confirm consistent results. For challenging applications like mass spectrometry, where shotgun proteomics cannot differentiate between FPR1 and FPR2 due to sequence homology, additional methodological approaches such as targeted proteomics with unique peptide identification should be considered . When interpreting results from published studies, researchers should critically evaluate the antibody validation methods employed and consider possible cross-reactivity issues. Finally, when designing blocking experiments, use multiple FPR2 antagonists with different chemical structures to confirm that observed effects are specifically due to FPR2 blockade rather than off-target effects.

What factors influence reproducibility in FPR2 functional assays?

Reproducibility challenges in FPR2 functional assays stem from multiple biological and technical variables that require careful consideration and standardization. First, donor variability significantly impacts FPR2 expression and function, particularly across sex and age demographics . To address this, researchers should include demographic information in reports and consider pooling samples only within comparable demographic groups. Cell isolation techniques can substantially affect FPR2 functionality, as prolonged processing may alter receptor expression or induce partial activation. Standardized, rapid isolation protocols with minimal manipulation are recommended . For macrophage-based assays, polarization protocols must be rigorously standardized, with detailed reporting of cytokine concentrations, timing, and culture conditions. The cellular microenvironment dramatically influences FPR2 function, with hypoxic conditions particularly relevant to tumor-associated macrophage studies . Researchers should carefully control oxygen levels when modeling tumor environments. Additionally, researchers should be aware that passage number affects FPR2 expression in immortalized cell lines, necessitating consistent use of cells within a defined passage range. For agonist/antagonist studies, stock solution preparation methods, storage conditions, and exposure time must be standardized and reported in detail, as these compounds may degrade or aggregate under variable conditions .

How should researchers interpret contradictory findings in FPR2 signaling studies?

Contradictory findings in FPR2 signaling studies frequently arise from methodological differences, biological complexities, and context-dependent effects that require careful interpretation. First, researchers should recognize that FPR2 exhibits ligand-biased signaling, where different ligands (e.g., lipoxin A4 vs. formyl peptides) can activate distinct downstream pathways despite binding to the same receptor . This phenomenon may explain why different studies report seemingly contradictory outcomes. When evaluating contradictory literature, researchers should carefully compare the specific ligands used, their concentrations, and exposure durations. Additionally, the cell type studied significantly impacts FPR2 signaling outcomes, with neutrophils, monocytes, and macrophages exhibiting distinct response patterns . The activation state of cells (e.g., naïve vs. primed) also dramatically influences FPR2 signaling, as receptor expression and coupling to downstream effectors may vary with cellular activation. Recent findings regarding sex-dependent FPR2 signaling introduce another layer of complexity, with female-derived cells showing distinct response patterns compared to male-derived cells in certain contexts . When interpreting conflicting data, researchers should evaluate whether sex differences might explain discrepancies. Finally, researchers should consider the microenvironmental context, as factors such as hypoxia, pH, and the presence of other inflammatory mediators can substantially modify FPR2 signaling outcomes.

What novel methodologies are advancing FPR2 research beyond traditional antibody applications?

Recent technological advances have expanded the methodological toolkit for FPR2 research beyond traditional antibody-based approaches. CRISPR-Cas9 gene editing now enables precise modification of FPR2 in primary human cells and development of reporter cell lines with fluorescent or luminescent readouts coupled to FPR2 activation . These systems allow real-time monitoring of receptor activity and facilitate high-throughput screening of potential agonists and antagonists. Advanced imaging techniques, including super-resolution microscopy and intravital imaging, provide unprecedented spatial resolution for studying FPR2 localization, trafficking, and interaction with signaling partners in living cells and tissues . Single-cell RNA sequencing and proteomics approaches have revealed previously unrecognized heterogeneity in FPR2 expression across immune cell subpopulations and disease states, enabling more nuanced phenotyping beyond traditional surface marker classifications . For researchers interested in translational applications, patient-derived organoids and humanized mouse models offer more physiologically relevant systems for studying FPR2 biology in disease contexts, particularly in cancer, where tumor-immune interactions are complex and difficult to model in traditional systems . These emerging methodologies provide powerful complements to antibody-based approaches, enabling more comprehensive analysis of FPR2 biology across scales from molecular interactions to in vivo function.

How can researchers effectively study the interplay between FPR2 and other inflammatory mediators?

Studying the complex interplay between FPR2 and other inflammatory mediators requires integrated experimental approaches that capture system-level interactions rather than isolated pathways. Multiplex cytokine analysis represents an essential methodology for simultaneously quantifying multiple inflammatory mediators in FPR2-modulated systems, allowing researchers to identify coordinated changes across cytokine networks . When implementing this approach, researchers should include both pro-inflammatory (TNF-α, IL-6) and pro-resolving factors (TGF-β, IL-10) to capture the full spectrum of inflammatory dynamics. Proximity ligation assays and co-immunoprecipitation combined with mass spectrometry enable detection of physical interactions between FPR2 and other receptors or signaling molecules, revealing potential cross-talk mechanisms . For functional studies, careful design of sequential stimulation experiments can illuminate how prior activation of other pathways modifies FPR2 responses, or vice versa. Researchers should establish detailed time courses rather than single endpoints to capture the dynamic nature of inflammatory responses . In vivo, conditional knockout models allow temporal control over FPR2 deletion, enabling studies of how FPR2 functions at different phases of inflammatory responses. When interpreting results, researchers should adopt network analysis approaches rather than linear pathway models, as inflammatory systems typically involve multiple feedback and feedforward loops that create complex, emergent behaviors beyond simple cause-effect relationships.

What control conditions are critical for valid interpretation of FPR2 antibody experiments?

Robust control conditions are essential for valid interpretation of FPR2 antibody experiments across applications. For antibody specificity controls, researchers should include FPR2 knockout/knockdown samples whenever possible, as these represent the gold standard for validating antibody specificity . When genetic approaches are not feasible, peptide blocking experiments using the immunizing peptide can help confirm specific binding. For flow cytometry applications, comprehensive controls should include not only isotype controls matched to the FPR2 antibody class and concentration but also fluorescence-minus-one (FMO) controls to establish proper gating strategies . In functional studies involving FPR2 activation or inhibition, vehicle controls must be carefully matched to the solvent used for agonists/antagonists, as DMSO and other common solvents can themselves affect cellular responses at higher concentrations . When studying FPR2-mediated effects on immune cell functions, researchers should include direct treatment controls to rule out direct effects of FPR2 ligands on effector cells independent of FPR2-expressing cells . For instance, when examining how FPR2-activated macrophages affect T cells, controls should include T cells directly exposed to FPR2 ligands without macrophages present. Additionally, considering the sex dimorphism in FPR2 function, sex-matched controls are essential, and samples from male and female donors should be analyzed separately rather than pooled .

How should quantitative data from FPR2 studies be analyzed and presented?

Quantitative analysis and presentation of FPR2 research data require careful consideration of statistical approaches and visualization methods that accurately represent biological complexity while enabling meaningful interpretation. For flow cytometry data measuring FPR2 expression, researchers should report both percentage of positive cells and median fluorescence intensity (MFI) to capture both the proportion of expressing cells and the expression level per cell . When analyzing dose-response relationships for FPR2 agonists or antagonists, nonlinear regression models should be applied to determine EC50/IC50 values, with 95% confidence intervals reported rather than point estimates alone . Time-course experiments should be analyzed using repeated measures statistical approaches that account for within-subject correlations over time. For sex-specific analyses, data should be presented with clear delineation between male and female samples, avoiding pooling across sexes given the established sex dimorphism in FPR2 function . Correlation analyses between FPR2 expression and functional outcomes should employ appropriate methods based on data distribution, with Spearman correlation preferred for non-normally distributed data. The following table illustrates recommended statistical approaches for common FPR2 research scenarios:

When presenting results, researchers should provide complete methodological details to enable reproducibility, including antibody catalog numbers, dilutions, incubation conditions, and equipment settings .

How does research on FPR2 inform potential therapeutic approaches for inflammatory conditions?

Research on FPR2 has revealed significant therapeutic potential for inflammatory conditions, particularly through the development of selective FPR2 agonists that promote resolution of inflammation. Recent structure-activity-relationship (SAR) studies have yielded potent and selective FPR2 agonists from imidazole and benzimidazole chemotype series, with some compounds demonstrating low nanomolar potency and >10,000-fold selectivity over FPR1 in calcium release assays . These selective agonists have shown promising efficacy in multiple animal models of asthma, suggesting FPR2 activation as a viable therapeutic approach for treating inflammatory airway diseases . The mechanistic rationale for this approach stems from FPR2's role in mediating pro-resolving signaling pathways that actively terminate inflammatory processes rather than simply blocking pro-inflammatory mediators. When designing preclinical studies to evaluate FPR2-targeted therapeutics, researchers should include both acute and chronic inflammation models to assess effects on both initiation and resolution phases. Additionally, sex-stratified analysis is essential given the documented sexual dimorphism in FPR2 function . While most current research focuses on FPR2 agonism, some inflammatory contexts might benefit from antagonist approaches, particularly in cancer settings where FPR2+ macrophages may contribute to immunosuppression . For translational relevance, researchers should evaluate FPR2-targeted compounds in humanized models that better recapitulate human immune responses compared to conventional animal models.

What considerations should guide FPR2-focused cancer immunotherapy research?

Cancer immunotherapy research targeting FPR2 requires careful consideration of mechanistic complexity, contextual factors, and sex-dependent effects to develop effective therapeutic strategies. Recent findings indicate that FPR2 shapes an immune-excluded pancreatic tumor microenvironment, functioning as a sex-dependent mediator of macrophage immunosuppression . In female patients, FPR2 expression correlates with an M2/M1 macrophage ratio and poorer prognosis, suggesting sex-specific therapeutic opportunities . When designing FPR2-targeted cancer immunotherapy studies, researchers should first establish comprehensive immune profiling of tumor samples, correlating FPR2 expression with immune infiltration patterns, checkpoint molecule expression, and clinical outcomes. Flow cytometry panels should include markers for FPR2 alongside M1/M2 polarization markers to characterize the phenotype of FPR2+ tumor-associated macrophages . For preclinical evaluation of FPR2 antagonists in cancer models, combination approaches with established immunotherapies (checkpoint inhibitors, CAR-T cells) should be considered, as FPR2 blockade may enhance responsiveness to these modalities by reprogramming the immunosuppressive microenvironment. Researchers must implement sex-stratified analysis in all studies, as the therapeutic benefit of FPR2 targeting may be more pronounced in female patients based on current evidence . Additionally, spatial analysis of FPR2+ cells relative to tumor boundaries and T cell infiltrates provides crucial information about how FPR2 contributes to immune exclusion mechanisms that limit immunotherapy efficacy.